Moderna Inc (MRNA)
106.58
-4.03
(-3.64%)
USD |
NASDAQ |
Mar 28, 16:00
107.00
+0.42
(+0.39%)
After-Hours: 19:17
Moderna Enterprise Value: 33.75B for March 27, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 27, 2024 | 33.75B |
March 26, 2024 | 32.52B |
March 25, 2024 | 33.66B |
March 22, 2024 | 31.76B |
March 21, 2024 | 31.25B |
March 20, 2024 | 30.86B |
March 19, 2024 | 31.64B |
March 18, 2024 | 31.32B |
March 15, 2024 | 31.16B |
March 14, 2024 | 31.01B |
March 13, 2024 | 32.18B |
March 12, 2024 | 33.68B |
March 11, 2024 | 34.27B |
March 08, 2024 | 30.84B |
March 07, 2024 | 29.48B |
March 06, 2024 | 28.88B |
March 05, 2024 | 27.91B |
March 04, 2024 | 28.08B |
March 01, 2024 | 27.72B |
February 29, 2024 | 26.64B |
February 28, 2024 | 28.64B |
February 27, 2024 | 28.15B |
February 26, 2024 | 27.32B |
February 23, 2024 | 28.25B |
February 22, 2024 | 29.39B |
Date | Value |
---|---|
February 21, 2024 | 24.86B |
February 20, 2024 | 24.63B |
February 16, 2024 | 25.16B |
February 15, 2024 | 26.21B |
February 14, 2024 | 24.23B |
February 13, 2024 | 24.01B |
February 12, 2024 | 25.39B |
February 09, 2024 | 24.79B |
February 08, 2024 | 27.17B |
February 07, 2024 | 29.33B |
February 06, 2024 | 29.61B |
February 05, 2024 | 27.87B |
February 02, 2024 | 28.64B |
February 01, 2024 | 29.22B |
January 31, 2024 | 30.00B |
January 30, 2024 | 30.54B |
January 29, 2024 | 31.44B |
January 26, 2024 | 30.29B |
January 25, 2024 | 30.67B |
January 24, 2024 | 30.02B |
January 23, 2024 | 30.33B |
January 22, 2024 | 29.48B |
January 19, 2024 | 29.48B |
January 18, 2024 | 29.24B |
January 17, 2024 | 29.73B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.978B
Minimum
Aug 05 2019
187.56B
Maximum
Aug 09 2021
43.16B
Average
38.94B
Median
Enterprise Value Benchmarks
Gilead Sciences Inc | 108.59B |
Johnson & Johnson | 386.89B |
Eli Lilly and Co | 762.26B |
Merck & Co Inc | 361.69B |
Pfizer Inc | 215.30B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 217.00M |
Revenue (Quarterly) | 2.813B |
Total Expenses (Quarterly) | 2.807B |
EPS Diluted (Quarterly) | 0.55 |
Gross Profit Margin (Quarterly) | 66.97% |
Profit Margin (Quarterly) | 7.71% |
Earnings Yield | -11.64% |
Normalized Earnings Yield | -11.51 |